Mirum Pharmaceuticals, Inc. (MIRM) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $84.34 (-2.37%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Gavin Clark-Gartner | Evercore ISI | $126.00 | +49.4% |
| Feb 26, 2026 | Mani Foroohar | Leerink Partners | $118.00 | +39.9% |
| Feb 26, 2026 | Joe Kim | RBC Capital | $128.00 | +51.8% |
| Dec 11, 2025 | Steven Seedhouse | Raymond James | $110.00 | +30.4% |
| Dec 9, 2025 | Michael Ulz | Morgan Stanley | $95.00 | +12.6% |
| Dec 8, 2025 | Brian Skorney | Robert W. Baird | $88.00 | +4.3% |
| Nov 5, 2025 | Swayampakula Ramakanth | H.C. Wainwright | $81.00 | -4.0% |
| Aug 11, 2025 | James Condulis | Stifel Nicolaus | $89.00 | +5.5% |
| Aug 7, 2025 | Jonathan Wolleben | JMP Securities | $81.00 | -4.0% |
| Nov 12, 2024 | Dae Gon Ha | Stifel Nicolaus | $70.00 | -17.0% |
| Aug 8, 2024 | Brian Skorney | Robert W. Baird | $44.00 | -47.8% |
| Jun 17, 2024 | Gavin Clark-Gartner | Evercore ISI | $62.00 | -26.5% |
| Jun 17, 2024 | Michael E Ulz | Morgan Stanley | $57.00 | -32.4% |
| Jun 17, 2024 | Ed Arce | H.C. Wainwright | $66.00 | -21.7% |
| Jun 17, 2024 | Brian Skorney | Robert W. Baird | $39.00 | -53.8% |
| May 23, 2024 | Joshua Schimmer | Cantor Fitzgerald | $45.00 | -46.6% |
| Apr 16, 2024 | Dae Gon Ha | Stifel Nicolaus | $48.00 | -43.1% |
| Mar 14, 2024 | Ed Arce | H.C. Wainwright | $58.00 | -31.2% |
Top Analysts Covering MIRM
MIRM vs Sector & Market
| Metric | MIRM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 25 | 8 | 19 |
| Target Upside | +81.7% | +153002.0% | +21.5% |
| P/E Ratio | -201.97 | 3.66 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $172M | $176M | $180M | 4 |
| 2027-03-31 | $173M | $177M | $181M | 4 |
| 2027-06-30 | $189M | $194M | $199M | 3 |
| 2027-09-30 | $204M | $209M | $214M | 3 |
| 2027-12-31 | $225M | $231M | $237M | 3 |
| 2028-12-31 | $997M | $997M | $997M | 7 |
| 2029-12-31 | $1.21B | $1.29B | $1.35B | 3 |
| 2030-12-31 | $1.51B | $1.60B | $1.69B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.51 | $-0.49 | $-0.48 | 4 |
| 2027-03-31 | $-0.47 | $-0.46 | $-0.45 | 2 |
| 2027-06-30 | $0.04 | $0.04 | $0.04 | 2 |
| 2027-09-30 | $0.14 | $0.14 | $0.14 | 2 |
| 2027-12-31 | $0.36 | $0.37 | $0.38 | 2 |
| 2028-12-31 | $-0.16 | $1.87 | $4.41 | 6 |
| 2029-12-31 | $4.60 | $4.99 | $5.31 | 4 |
| 2030-12-31 | $7.14 | $7.74 | $8.25 | 2 |
Frequently Asked Questions
What is the analyst consensus for MIRM?
The consensus among 25 analysts covering Mirum Pharmaceuticals, Inc. (MIRM) is Buy with an average price target of $140.20.
What is the highest price target for MIRM?
The highest price target for MIRM is $128.00, set by Joe Kim at RBC Capital on 2026-02-26.
What is the lowest price target for MIRM?
The lowest price target for MIRM is $39.00, set by Brian Skorney at Robert W. Baird on 2024-06-17.
How many analysts cover MIRM?
25 analysts have issued ratings for Mirum Pharmaceuticals, Inc. in the past 12 months.
Is MIRM a buy or sell right now?
Based on 25 analyst ratings, MIRM has a consensus rating of Buy (2.00/5) with a +81.7% upside to the consensus target of $140.20.
What are the earnings estimates for MIRM?
Analysts estimate MIRM will report EPS of $-0.49 for the period ending 2026-12-31, with revenue estimated at $176M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.